Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Carretera Colmenar Viejo km 9100, 28034, Madrid, Spain.
Transl Lung Cancer Res. 2013 Jun;2(3):189-99. doi: 10.3978/j.issn.2218-6751.2013.03.02.
Locally advanced or stage III disease accounts for ~30% of patients with non-small-cell lung cancer (NSCLC), which means only in the United States, more than 50,000 new patients each year. Stage III is a very heterogeneous disease, the management of patients is complex and several conditions (performance status, weight loss, comorbidities, characteristics of nodal involvement or resectability) must be considered before selecting the best treatment, which in most cases is chemotherapy (CT) and radiotherapy (RT). In this article, we will review key changes in the management of unresectable stage III during the last decades. Also we will highlight some challenges and areas of active research.
局部晚期或 III 期疾病占非小细胞肺癌 (NSCLC) 患者的约 30%，这意味着仅在美国，每年就有超过 50,000 例新患者。III 期是一种非常异质的疾病，患者的管理非常复杂，在选择最佳治疗方法之前，必须考虑多种情况（体能状态、体重减轻、合并症、淋巴结受累或可切除性的特点），在大多数情况下，治疗方法是化疗 (CT) 和放疗 (RT)。本文将回顾过去几十年中不可切除 III 期疾病管理方面的重要变化。同时，我们将重点介绍一些具有挑战性和活跃研究领域。
